Daily Bulletin 2017

Annual Oration in Radiation Oncology Presented Today

Wednesday, Nov. 29, 2017

How Personalized Medicine will Transform Radiation Oncology

Daphne Haas-Kogan, MD, will present the Annual Oration in Radiation Oncology, entitled, "Personalized Medicine and Radiation Oncology," on Wednesday, Nov. 29, at 1:30 p.m. in Room E450A.



Dr. Haas-Kogan will focus on how personalized medicine has already changed radiation oncology and how it will change the specialty in the future. She will discuss the promise of radiomic imaging, which is successfully defining imaging biomarkers based on quantitative descriptions of tumor phenotypes to improve predictions of treatment response and prognosis while reducing radiation doses to organs at risk and maximizing doses to cancerous lesions.

In addition, Dr. Haas-Kogan will discuss the commitment needed from radiation oncologists to engineer drugs and design approaches that target a tumor specifically while sparing a patient's normal tissues. Finally, she will explore the new class of MRI devices that is creating a paradigm shift in radiation therapy delivery.

Dr. Haas-Kogan is chair of the Department of Radiation Oncology at Dana-Farber Cancer Institute, Brigham and Women's Hospital and Boston Children's Hospital. She holds the Radiation Oncology Endowed Professorship at Harvard Medical School and is a member of the Association of American Physicians. She received her MD from UCSF and also completed a radiation oncology residency and post-doctoral fellowship in molecular neuro-oncology. She received a 1997 RSNA Research Scholar Grant for her work in molecular determinants of the cellular response to ionizing radiation. While at UCSF she served as vice chair for research and as educational program director.

Throughout her career, Dr. Haas-Kogan has maintained a productive, well-funded basic science laboratory in which she investigates signaling aberrations in human cancers, including adult and pediatric brain tumors. She has been the principal investigator on many grants funded by NIH/NCI, philanthropic organizations and industry collaborations.

Dr. Haas-Kogan is a member of the Blue Ribbon Panel appointed to inform the scientific direction and goals of the National Cancer Institute's Cancer Moonshot.

Tip of the day:

In CT contrast studies, lowering kVp can reduce both radiation and contrast dose.

The RSNA 2017 Daily Bulletin is owned and published by the Radiological Society of North America, Inc., 820 Jorie Blvd., Oak Brook, IL 60523.